

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 25, 2022

Lantern Pharma Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction
of Incorporation)

001-39318

(Commission File Number)

46-3973463

(I.R.S. Employer
Identification Number)

1920 McKinney Avenue, 7th Floor
Dallas, Texas 75201
(Address of principal executive offices)

(972) 277-1136

(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock: Par value \$.001	LTRN	Nasdaq Capital Market

Item 8.01 Other Information.

Lantern Pharma Disclosure Channels to Disseminate Information

Lantern Pharma's investors and others should note that we announce material information to the public about our company and its technologies, clinical developments, licensing matters and other matters through a variety of means, including Lantern Pharma's website, press releases, SEC filings, digital newsletters and social media, in order to achieve broad, non-exclusionary distribution of information to the public. We encourage our investors and others to review the information we make public in the locations below as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Interested in keeping up with Lantern Pharma?

For more information on Lantern Pharma and its technology, clinical developments, licensing matters and other matters, please visit <https://www.lanternpharma.com/>

For more information for Lantern Pharma's investors, please visit: <https://ir.lanternpharma.com/>

For the latest information from Lantern Pharma, including press releases and presentations, please visit: <https://ir.lanternpharma.com/events-presentations/events>. Investors and other interested parties can subscribe to our press releases at the aforementioned address.

For additional information, please follow Lantern Pharma's social media accounts at:

Twitter: <https://twitter.com/LanternPharma>

LinkedIn: <https://www.linkedin.com/company/lanternpharma>

Investors and other interested parties can also subscribe to our social media accounts at the aforementioned addresses.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 25, 2022

LANTERN PHARMA INC.

/s/ David Margrave

David Margrave,
Chief Financial Officer

2